Clinical Trial Update: A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma [Phase 2]

View source ↗

Summary

Phase IIb trial of Vigil, an autologous tumor cell immunotherapy, in Ewing's Sarcoma completed with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma

Drugs mentioned

• Vigil

Snippet

Sponsor: Gradalis, Inc. | Conditions: Ewing's Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2022-07-22